Everolimus in Treating Patients WIth Recurrent or Metastatic Breast Cancer

NCT ID: NCT00255788

Last Updated: 2023-08-04

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 49 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-05-10
• Study Completion Date: 2011-01-18

Brief Summary

RATIONALE: Everolimus may stop the growth of tumor cells by blocking blood flow to the tumor.

PURPOSE: This randomized phase II trial is studying two different schedules of everolimus to see how well they work in treating patients with recurrent or metastatic breast cancer.

Detailed Description

OBJECTIVES:

Primary

• Determine the efficacy of 2 different treatment schedules of everolimus, in terms of clinical/radiological response and early progression, in patients with recurrent or metastatic breast cancer.

Secondary

• Determine the time to progression and response duration in patients treated with these regimens.
• Determine the toxic effects of these regimens in these patients.
• Correlate molecular markers of mTOR activity in tumor tissue with objective tumor response in patients treated with these regimens.

OUTLINE: This is a randomized, open label, multicenter study. Patients are stratified according to presence of visceral metastases (yes vs no) and prior chemotherapy regimens for recurrent disease (0 vs 1). Patients are randomized to 1 of 2 treatment arms.

• Arm I: Patients receive oral everolimus once daily on days 1-28.
• Arm II: Patients receive oral everolimus on days 1, 8, 15, and 22. In both arms, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed at 4 weeks and then periodically until disease progression.

PROJECTED ACCRUAL: A total of 60 patients (30 per treatment arm) will be accrued for this study.

Conditions

Breast Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Arm A

Everolimus - 28 days q 4 wk

Group Type: ACTIVE_COMPARATOR

everolimus

Intervention Type: DRUG

Arm B

Everolimus - days 1, 8, 15 and 22 q 4wks

Group Type: ACTIVE_COMPARATOR

everolimus

Intervention Type: DRUG

Interventions

everolimus

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed breast cancer

• Metastatic or recurrent disease
• Considered incurable
• Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques or ≥ 10 mm by spiral CT scan
• Two primary breast cancers allowed
• Paraffin-embedded primary or metastatic tumor sample available
• No known brain metastases
• Hormone receptor status:

• Not specified

PATIENT CHARACTERISTICS:

Sex

• Male or female

Menopausal status

• Not specified

Performance status

• ECOG 0-2

Life expectancy

• Not specified

Hematopoietic

• Absolute granulocyte count ≥ 1,500/mm^3
• Platelet count ≥ 100,000/mm^3

Hepatic

• Bilirubin ≤ 1.5 times upper limit of normal (ULN)
• AST and ALT ≤ 2.5 times ULN

Renal

• Creatinine ≤ 1.5 times ULN

Other

• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No active uncontrolled infection
• No upper gastrointestinal condition or other condition that would preclude ability to take oral medication
• No other serious medical condition that would preclude study participation
• No psychiatric illness or neurologic disorder that would preclude study compliance
• No other malignancy within the past 5 years except curatively treated nonmelanoma skin cancer or carcinoma in situ of the cervix or bladder

PRIOR CONCURRENT THERAPY:

Chemotherapy

• At least 4 weeks since prior chemotherapy
• Prior adjuvant chemotherapy allowed
• No more than 1 prior chemotherapy regimen for metastatic or recurrent disease

Endocrine therapy

• At least 5 days since prior hormonal therapy

Radiotherapy

• At least 4 weeks since prior radiotherapy except for low-dose, limited-fraction, palliative, nonmyelosuppressive radiotherapy, defined as radiotherapy to < 20% of functioning bone marrow
• If prior radiotherapy was to sole site of disease, must have subsequent documented disease progression at that site

Surgery

• At least 3 weeks since prior major surgery

Other

• Concurrent prophylactic bisphosphonates allowed, if started prior to study entry
• No concurrent potent inhibitors of cytochrome 3A4, such as erythromycin, diltiazem, or ketoconazole and similar antifungals
• No other concurrent anticancer therapy
• No other concurrent investigational agents
• No concurrent grapefruit juice

• Minimum Eligible Age: 16 Years
• Maximum Eligible Age: 120 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

NCIC Clinical Trials Group

NETWORK

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Susan Ellard, MD

Role: STUDY_CHAIR

British Columbia Cancer Agency - Centre for the Southern Interior

Karen A. Gelmon, MD

Role: STUDY_CHAIR

British Columbia Cancer Agency

Locations

British Columbia Cancer Agency - Centre for the Southern Interior

Kelowna, British Columbia, Canada

Fraser Valley Cancer Centre at British Columbia Cancer Agency

Surrey, British Columbia, Canada

British Columbia Cancer Agency - Vancouver Cancer Centre

Vancouver, British Columbia, Canada

Margaret and Charles Juravinski Cancer Centre

Hamilton, Ontario, Canada

Toronto Sunnybrook Regional Cancer Centre at Sunnybrook and Women's College Health Sciences Centre

Toronto, Ontario, Canada

Countries

Canada

References

Ellard SL, Clemons M, Gelmon KA, Norris B, Kennecke H, Chia S, Pritchard K, Eisen A, Vandenberg T, Taylor M, Sauerbrei E, Mishaeli M, Huntsman D, Walsh W, Olivo M, McIntosh L, Seymour L. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol. 2009 Sep 20;27(27):4536-41. doi: 10.1200/JCO.2008.21.3033. Epub 2009 Aug 17.

Reference Type: RESULT

PMID: 19687332 (View on PubMed)

Other Identifiers

CAN-NCIC-IND163

Identifier Type: OTHER

Identifier Source: secondary_id

NOVARTIS-CAN-NCIC-IND163

Identifier Type: OTHER

Identifier Source: secondary_id

CDR0000450849

Identifier Type: OTHER

Identifier Source: secondary_id

I163

Identifier Type: -

Identifier Source: org_study_id